Oxford Immunotec Takes Active Role in Raising Awareness of TB Testing and Prevention during World TB Day

OXFORD, United Kingdom and MARLBOROUGH, Mass., March 24, 2016 -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the company’s commitment to building awareness of TB testing and prevention during World TB Day on March 24, 2016 through its support of educational programs around the world.

In recognition of World TB Day, Oxford Immunotec will be actively supporting and participating in many important symposia and events focused on the prevention and management of TB, including the Annual Tuberculosis Symposium at the London School of Hygiene and Tropical Medicine's TB Centre, the HIV Diagnostics Conference in Atlanta, Georgia and the World TB Symposium at Rutgers New Jersey Medical School.  Further, Oxford Immunotec will host a special presentation by renowned TB expert Elizabeth Talbot, MD, Associate Professor of Medicine at Geisel School of Medicine, Dartmouth College, Hanover, NH, at its US headquarters in Marlborough, Massachusetts, Dr. Talbot will present  “Advances in TB: A Year in Review”.

“A critical step in the effort to eliminate TB is building broader awareness among healthcare providers of the risk factors and the need for continued vigilance along with targeted, efficient and effective TB screening and screening follow up,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “Our commitment to education regarding the continued global threat posed by TB and the benefits of screening programs using the T-SPOT^®.TB test aim to expand understanding that TB is a preventable disease and that TB testing programs save thousands of lives each year.”

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions.  The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market.  In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media Inquiries:
Caroline Crawley 
Oxford Immunotec
Tel: +44 1235 442796
[email protected]

For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
[email protected]

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
[email protected]